Novo to Unveil Heart Study Details at US Meeting in November
- Results will provide detail on risk of each cardio disease
- Demand for Wegovy may reach ‘daunting volumes,’ CEO says
This article is for subscribers only.
Novo Nordisk A/S plans to publish the detailed data from its key trial looking at the cardiovascular impact of its hit obesity drug at a US conference in November.
The Danish drugmaker is targeting the American Heart Association’s scientific meeting in Philadelphia this year to disclose the results, Martin Holst Lange, Novo’s head of development, said in an interview Thursday. Publication at the event is yet to be confirmed.